Humanigen

hospitalizations have surpassed 100,000 patients, nearly doubling since the start of August in The United States. The last time the United States reported numbers like this was in January. Deaths related to COVID-19 are on the rise due to the Delta variant and as hospitalizations have climbed, adequate and qualified healthcare staffing has become an issue in some states.

Idaho hospitals reported that the number of patients in the ICU with COVID-19 has reached an all-time high across the state since the start of the pandemic. As hospitalization rates continue to increase there remains a continued need for effective therapeutics.



Read more:

U.S. Covid-19 Hospitalizations Nearly Doubled in August as Some States Ask for Resources They surpassed 100,000 for the first time since January, and some states have asked for federal assistance to handle the deluge of patients.

According to a recent article from The Guardian discussing the seasonal pattern of both the flu and , countries with temperate climates were found to have higher number of COVID-19 cases during the winter months, when temperature and humidity were low. Meanwhile, in countries with tropical climates the cases peaked during the summer monsoons, when humidity was high.

The results, published in the journal GeoHealth, reveal that there were two variables – ultraviolet levels and air-drying capacity – that consistently correlated with Covid-19 levels in all countries. Bright sunshine and fast evaporation were associated with falling rates of coronavirus, while cloudy skies and slow evaporation appear to aid the spread of the virus.

Within the next coming months, especially as winter approaches, it's important that we highlight the need for treatments. ’s treatment drug is intended for patients who are newly hospitalized with pneumonia, but not yet on mechanical ventilation; however, it is not yet authorized, or approved, in any country.



Read more:

Does Covid-19 follow a similar seasonal pattern to flu? Anticipating the seasonality of coronavirus is a key factor in fighting its spread, say scientists

A recent article from Endpoints News covered Genentech and Roche’s drug Actemra and the road to EUA. Actemra was granted Emergency Use Authorization by the FDA to treat despite some mixed data, but 11,000-patient analysis displayed it cut the risk of death. Now as vaccination rates decline and cases are increasing the companies hospitals are running out of supply of Actemra.

Humanigen’s drug lenzilumab, which is awaiting Emergency Use Authorization from the FDA, has met its primary endpoint of the Phase 3 LIVE-AIR trial with a 1.54-fold relative improvement in the likelihood of survival without the need for invasive mechanical ventilation (survival without ventilation, or ‘SWOV’) compared to placebo. Lenzilumab also improved the relative likelihood of SWOV by 1.92-fold in subjects who received both corticosteroids and remdesivir as well as a 3-fold improvement in the likelihood of SWOV in patients with a CRP

After the long, grueling path to EUA, Roche says there is a supply shortage of Actemra Genentech and Roche's drug Actemra was granted emergency use authorization by the FDA for Covid-19 despite some mixed data, but an 11,000-patient analysis soon showed it cut the risk of death. Less than two months after that analysis, the companies are running out of supply of the drug, and they've